Clinical Trials Logo
  1. Home
  2. Lennox-Gastaut Syndrome
  3. NCT01405053

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome Clinical Trial

Official title:
A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome

Clinical Trial Summary

This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01405053
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 3
Start date June 16, 2011
Completion date November 2, 2015
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT04133480 - Investigation of Cognitive Outcomes With Cannabidiol Oral Solution Phase 4
Recruiting NCT02632149 - Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome Phase 0
Active, not recruiting NCT05626634 - Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Phase 2
Completed NCT01151540 - A Long Term Extension Study of E2080 in Lennox-Gastaut Patients Phase 3
Completed NCT00552045 - Epilepsy Phenome/Genome Project
Completed NCT00004776 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome Phase 3
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Completed NCT01146951 - A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304) Phase 3
Completed NCT01991041 - European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS) N/A
Completed NCT02175173 - Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
Completed NCT02224573 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes Phase 3
Completed NCT00004729 - Ketogenic Diet for Child Epilepsy and Seizure Control N/A
Terminated NCT02815540 - The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy Phase 1/Phase 2
Withdrawn NCT02318537 - Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome Phase 3
Completed NCT01160770 - Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome Phase 3
Completed NCT03650452 - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies Phase 2
Withdrawn NCT01370486 - Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Phase 4
Completed NCT02731300 - Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study Phase 4
Completed NCT02224690 - A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults Phase 3